Friday, 16 October 2026European Markets

NEXITY Stock Was 10.75% Up Today

Loading stream...

(vianews) - the market ended the session with nexity (nxi.pa) jumping 10.75% to €17.21 on monday, after five consecutive sessions in a row of gains. cac 40 fell 0.03% to €7,568.82, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

nexity's last close was €17.21, 39.7% below its 52-week high of €28.54.

about nexity

nexity sa operates as a real estate company in europe and internationally. the company operates through development, services, and other activities divisions. it develops new homes and subdivisions; and new or refurbished office buildings, high-rises building, business parks, logistics facilities, retail property, hotels, and other industrial spaces. the company also provides property management services comprising rental management, sales and lettings, and condominium managing agent services, as well as manages serviced residences for students; distributes real estate products under the iselection and perl brands; offers insurance brokerage and asset management services; and real estate services, including rental management and property management services, consulting, and short-term rental of working spaces. in addition, it engages in the villes and projets, and pre-development urban regeneration projects; and investment activities. the company serves individual, corporate, institutional, and local authority clients. nexity sa was founded in 1995 and is headquartered in paris, france.

earnings per share

as for profitability, nexity has a trailing twelve months eps of €2.26.

pe ratio

nexity has a trailing twelve months price to earnings ratio of 7.62. meaning, the purchaser of the share is investing €7.62 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.59%.

revenue growth

year-on-year quarterly revenue growth grew by 5.1%, now sitting on 4.44b for the twelve trailing months.

more news about nexity (nxi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com